Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAmortizatization of IntangiblesCapital ExpendituresCapital ExpendituresCash from Financing ActivitiesCash from Financing ActivitiesCash from Investing ActivitiesCash from Investing ActivitiesCash from OperationsCash from OperationsChange in Accured ExpensesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesChange in ReceivablesDepreciation & Amortization (CF)Depreciation & Amortization (CF)Free Cash FlowFree Cash FlowGains from Investment SecuritiesGains from Investment SecuritiesNet Cash FlowNet Cash FlowNet IncomeNon-cash ItemsNon-cash ItemsShare-based CompensationShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Celldex Therapeutics (CLDX) Cash from Investing Activities (2016 - 2025)

Celldex Therapeutics has reported Cash from Investing Activities over the past 16 years, most recently at $55.4 million for Q4 2025.

  • Quarterly results put Cash from Investing Activities at $55.4 million for Q4 2025, up 130.49% from a year ago — trailing twelve months through Dec 2025 was $209.1 million (up 172.06% YoY), and the annual figure for FY2025 was $209.1 million, up 172.06%.
  • Cash from Investing Activities for Q4 2025 was $55.4 million at Celldex Therapeutics, down from $60.8 million in the prior quarter.
  • Over the last five years, Cash from Investing Activities for CLDX hit a ceiling of $60.8 million in Q3 2025 and a floor of -$315.2 million in Q1 2024.
  • Median Cash from Investing Activities over the past 5 years was $23.6 million (2022), compared with a mean of -$15.7 million.
  • Biggest five-year swings in Cash from Investing Activities: skyrocketed 406.45% in 2023 and later crashed 4114.0% in 2024.
  • Celldex Therapeutics' Cash from Investing Activities stood at -$18.9 million in 2021, then surged by 264.76% to $31.2 million in 2022, then plummeted by 648.36% to -$171.2 million in 2023, then surged by 114.05% to $24.0 million in 2024, then surged by 130.49% to $55.4 million in 2025.
  • The last three reported values for Cash from Investing Activities were $55.4 million (Q4 2025), $60.8 million (Q3 2025), and $49.8 million (Q2 2025) per Business Quant data.